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lation corresponds to participating subjects since 2004 who received continuous
annual follow-up visits until 2009. The trend analysis of the different risk factors
over time was performed, as well as the estimate of the annual CVR using ATPIII
categories (High, moderate and lower risk). RESULTS: 3,870 subjects were included
in the assessment with a mean age of 62 years (SD11.52) and the majority of
subjects are women (73%). The results showed a reduction of 30% in smoking. In
addition, over the past 5 years, blood pressure (BP) diminished consistently
through risk groups (mean reduction of 14 mmHg); LDL cholesterol levels were
reduced within high and moderate risk groups (mean reduction of 25 mg/dl) and
the speed of kidney damage progression decreased. Complementary analyses with
an extended cohort containing over 8,000 patients exhibited similar results.
CONCLUSIONS: Cardiovascular Risk DM Program “De Todo Corazón” showed a
meaningful impact to modify risk factors in Colombian patients such as smoking,
BP, lipid profile and kidney risk. The results of a wider cohort supported that ob-
served positive outcomes trends were generated by this program.
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MEDICATION THERAPY MANAGEMENT IMPROVES HEALTH CARE UTILIZATION
AND COSTS FOR EMPLOYERS
Pinto SL, Partha G, Jania A
University of Toledo, Toledo, OH, USA
OBJECTIVES:Todetermine the health care utilization andpotential cost savings for
an employer-sponsored medication therapy management (MTM) program.
METHODS: A prospective, pre-post longitudinal study. Employees included in the
study were Lucas County employees and their dependents who had diabetes, hy-
pertension, hyperlipidemia, or a combination of the three. The MTM services were
provided by independent pharmacists from seven sites in Northwest Ohio. Vari-
ables measured included social measures (alcohol consumption, tobacco con-
sumption, exercise, caffeine consumption) and process measures (specialty phy-
sician visits, sick days, emergency room visits, flu shot, hypoglycemic events, and
self-monitoring of blood glucose). Difference in disease-related spending, pre-and
post joining MTM program were analyzed for employees who improved, did not
improve or showed negative improvement at their final recorded visit for process
measures. Data was analyzed using SPSS v17.0 and Microsoft Excel. RESULTS:
There was an overall trend of improvement in both the social and process mea-
sures being measured. All three specialty physician visits have increased: podia-
trist visits by 24%, ophthalmologist visits by 41%, and dentist visits by 26%. Average
cost savings for employees who improved or maintained appropriate utilization,
ranged from $931.67 to $1437.77 per employee per two years. Approximately 90% of
employees either took less or had the same amount of sick days. Employees who
had fewer sick days saved almost $1230.79 per employee while employees who
took more sick days spent approximately $2146.51 per employee. Employee utili-
zation of flu shots have been substantial, with 70% getting a flu shot at least once
over the 24 months. Alcohol and tobacco consumption decreased by 50% and 55%,
respectively. Caffeine use decreased by 26.47%. Reported exercise increased by
39%. CONCLUSIONS: Interaction with the pharmacist has had a positive impact on
employees’ outcomes related to social and process measures, which might also be
helpful in causing reduction in cost burden to the employer.
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OBJECTIVES: To assess the impact of an employer-sponsored, pharmacist-pro-
vided MTM program on clinical outcomes in patients with diabetes and hyperten-
sion over a 24 month period. METHODS: A prospective, intent-to-treat, pre-post
longitudinal study. Patients were Lucas County employees and dependents with
diabetes, hypertension, or a combination. The MTM services were provided by
independent pharmacists in Northwest Ohio at seven sites. ADA and JNC-VII
guidelines were used to design interventions and set patient goals. Data was ana-
lyzed using SPSS v17.0. Friedman testwas used to compare readings at baseline, 12,
and 24months. RESULTS: To date 623 patients have enrolled in the MTM program,
41 with diabetes only, 224 with diabetes and one or more comorbidities, 85 with
hypertension only, and 101 with hypertension with comorbidities. A total of 190
patients with A1C values and 412 patients with blood pressure values were ana-
lyzed.MeanA1C values increased from 7.14 1.53 to 7.28 1.52 for all patients. For
uncontrolled patients, A1C decreased from 8.40  1.57 to 8.03  1.63. Diabetes
patients decreased systolic blood pressure (SBP) from 133.59  19.57 to 129.65 
16.04 and diastolic blood pressure (DBP) from 81.95  10.38 to 79.49  8.72. Uncon-
trolled patients decreased SBP from 147.65  16.62 to 134.02  14.99 and DBP de-
creased from 87.65  6.66 to 82.31  8.31. Hypertensive patients decreased SBP
from 134.42  17.28 to 129.86  14.13 and DBP from 84.76  10.97 to 81.76  10.10.
Uncontrolled hypertensive patients decreased SBP from 151.89  11.10 to 134.95 
12.56 and DBP from 98.27 6.24 to 85.71 11.86. CONCLUSIONS: The pharmacists’
efforts have been shown to help decrease mean A1C and BP in patients. The im-
provements in these values help to decrease the risk for related complications and
additional employer costs.
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OBJECTIVES: To assess the relationship between integration of services and the
management of hypertensive patients within select physician organizations in the
U.S.METHODS:Amodified version of the Physician Practice Connection Readiness
Survey (PPC-RS), developed by the National Committee for Quality Assurance
(NCQA), was administered to chief medical officers at 28 U.S.-based physician or-
ganizations in 2010. The integration score included structural, functional, and fi-
nancial sub-domains with possible scores of 0 to 100; a higher score indicating
greater integration of services. Demographic and clinical data were collected from
a random sample of 300 hypertensive adults selected for chart review at each
participating organization. Site characteristics and integration scores were re-
ported. Hierarchical regression models were estimated to assess the association
between an organization’s integration score and patients’ outcomes. RESULTS: Of
the 28 participating sites, most had electronic medical records functions (71.4%)
and hadmore than 50 staffmembers (78.6%). The average integration scorewas 46,
with mean scores of 64, 33 and 42 for the structural, financial, and functional
sub-domains, respectively. Integration scores were generally higher in sites with
50 physicians as compared to sites with 50 physicians (52.8 vs. 36.6, respec-
tively), and were also higher in sites owned by hospitals. Among the 8,400 patients
reviewed, approximately 60.5% had controlled BP. A positive correlation was ob-
served between integration scores and controlled BP (Pearson coefficient  0.39,
p0.05). Additionally, patient BP control was better in organizations with integra-
tion scores in the highest quartile (64.3%) than in sites in the lowest quartile
(56.8%). Although the point estimates were not significant in the hierarchical
model, regression analyses suggested that higher integration scores were associ-
ated with better BP control outcomes. CONCLUSIONS: This study provides some
evidence that better integration of service in physician organizations is associated
with better patient outcomes as reported via the PPC-RS.
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OBJECTIVES: Antiplatelet therapies with aspirin, ADP receptor inhibitors, and gly-
coprotein IIb/IIIa inhibitors play an important role in management of acute coro-
nary syndromes and chronic coronary heart disease. An assessment of the litera-
ture was conducted to identify evidence gaps and critical unmet needs in
antiplatelet therapy in the management of ACS and chronic CHD. METHODS: A
targeted literature search was conducted on antiplatelet therapy with a focus on
ADP receptor inhibitors using PubMed, Medline and Google Scholar. Parallel
searches were initiated for the ACS and chronic CHD. Additional references were
identified and included based on citations from reviewed articles. A total of 179
articles were reviewed. Article types considered in the study included review arti-
cles, clinical trials, observational studies, and economic evaluations.RESULTS:The
review identified gaps and unmet needs in drug therapy for ACS and chronic CHD
using established (aspirin, clopidogrel, and glycoprotein IIb/IIIa agents) and newer
drugs (prasugrel and ticagrelor). Key evidentiary gapswere identified on the impact
of clopidogrel resistance, antiplatelet associatedmajor, minor and nuisance bleed-
ing risk, impact on humanistic outcomes, long term cost-effectiveness, impact on
elderly patients and other high risk subpopulations. Our assessment revealed that
current antiplatelet therapies are associated with significant downsides, such as
increased bleeding risks as well as other untoward effects. CONCLUSIONS: Our
assessment revealed important gaps and areas of unmet need associated with
current and new antiplatelet therapies in the management of ACS and chronic
CHD. Further studies should be conducted to address these evidentiary gaps, while
unmet patient needs should be taken into consideration in future drug develop-
ment.
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OBJECTIVES: To report the effectiveness of a CME intervention to improve appro-
priate care for hypertension, which in turn has a positive effect on blood pressure
control of hypertensive patients in primary care clinics. METHODS: A secondary
data analysis was carried out using data of hypertensive patients treated by family
doctors who participated in the CME intervention. The evaluation was designed as
a pre-/post-intervention study with control group in six primary care clinics. The
effect of the CME intervention was analysed using multiple logistic regression
modelling in which the dependent variable was uncontrolled blood pressure in the
postintervention patient measurement. The model was adjusted by considering
the family doctors as a cluster unit. This allowed correcting the effect of including
several patients who received treatment by the same doctor. Selection of regres-
sion variables was carried out by comparing 2 values of the log likelihood in the
models; this was carried out by using the backward stepwise procedure. Goodnes-
sof-fit of the model was evaluated using the Hosmer–Lemeshow test. RESULTS:
After the CME intervention, the net reduction of uncontrolled blood pressure be-
tween stages in the intervention group was 10.3%. The model results were that
being treated by a family doctor who participated in the CME intervention reduced
by 53% the probability of lack of control of blood pressure; receiving dietary recom-
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mendations reduced 57% the probability of uncontrolled blood pressure. Having
uncontrolled blood pressure at the baseline stage increased the probability of lack
of control in 166%, and per each unit of increase in body mass index the lack of
control increased 7%. CONCLUSIONS: CME intervention improved the medical de-
cision-making process to manage hypertension, thus increasing the probability of
hypertensive patients to have blood pressure under control.
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OBJECTIVES: The objective of the study was to examine rates of depression treat-
ment and variations in depression treatment by demographic, socioeconomic, ac-
cess to care, health status, and life-style characteristics among women with
hypertension. METHODS: The study design was cross-sectional, using data on
from 2006 and 2007 Medical Expenditure Panel Survey (MEPS), large-scale surveys
of families and individuals to provide nationally representative estimates of health
care use and expenditures. The study included 1304women aged 22 and older with
hypertension and depression, identified from MEPS medical condition files. Anti-
depressantswere identified fromprescription drug reports and psychotherapywas
identified from outpatient visits files. Depression treatment patterns by demo-
graphic, socioeconomic, healthcare access and health status were analyzed using
chi-square tests, logistic regression and multinomial logistic regressions. All anal-
ysis accounted for the complex design of the MEPS using SAS 9.2. RESULTS: In our
study sample, 23.9% had no depression treatment, 56.8% had antidepressant use
only, and 19.3% had psychotherapy with or without antidepressants. Among
womenwith hypertension and depression, African Americans (AOR 0.47), Latina
(AOR 0.46), and uninsured (AOR 0.39) were significantly less likely to report any
treatment for depression compared to Whites and those with private insurance.
Compared to no treatment, psychotherapy with or without antidepressants was
less likely among those with less than high school education and more likely
among women reporting fair/poor mental health. CONCLUSIONS: Nearly one-
quarter of women with hypertension did not have treatment for depression. Dis-
parities in depression treatment by race/ethnicity, health insurance, and education
status were noted. Further studies need to explore reasons for not receiving de-
pression treatment and whether such lack of treatment for depression is associ-
ated with poor health outcomes in these women.
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POST-MYOCARDIAL INFARCTION (MI) PATIENTS
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OBJECTIVES: To evaluate the effect of insurance status on the use of ARBs and ACE
inhibitors among post-Myocardial Infarction (MI) patients. METHODS: The 2007
full-year consolidated data from the Medical Expenditure Panel Survey (MEPS),
nationally representative survey, was used and linked with the prescribed medi-
cine data. A cross-sectional survey data analysiswas performed to evaluate the use
of ARBs and ACE inhibitors in patients diagnosed with Myocardial Infarction (MI)
and its relationship with patients’ insurance status. The outcome measures in-
cluded the binary variables of ACE inhibitor and ARB usage. A total of 464 post-MI
patients were included in the analyses by conducting multivariate logistic regres-
sion, controlling for socio-economic and demographic variables. RESULTS: Out of
464 patients with MI, 67 (14.44%) used only ARBs, 244 (52.59%) used only ACE inhib-
itors, 15 (3.23%) used both drugs, and 138 (29.74%) used neither ARBs nor ACE
inhibitors. Patients with Medicare coverage only and patients without insurance
were less likely to use ARBs, compared to patients with private insurance (adjusted
OR 0.26, p0.018; adjusted OR 0.03, p0.064, respectively). There was no significant
difference between health insurance status and use of ACE inhibitors. Further-
more, health insurance status was not significantly different among patients who
used neither ARBs nor ACE inhibitors. AmongMI patients who used both ARBs and
ACE inhibitors, patients with Medicare coverage only were less likely to use both
drugs (adjusted OR 0.02, p0.001), relative to patients with private insurance. Ad-
ditionally, patients with educational attainment of higher than college degrees
were more likely to use both drugs than those who did not finish college degrees
(adjusted OR 19.61, p0.042). CONCLUSIONS: Health insurance significantly af-
fected the usage of more expensive ARBs but not less expensive ACE inhibitors.
Policy makers need to be aware of the moral hazard arising from the insurance
coverage in drug use.
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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among elderly patients. METHODS: A retrospective cohort study was
conducted to examine predictors of statin selection among patients aged 365 years,
who initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS), or rosuvasta-
tin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined as the first
statin claim following at least 90 days of no statin access. Multiple logistic regres-
sion models were employed to assess predictive factors of PS initiation versus
other statin initiations. RESULTS:Of 96,450 statin users identified, there were 8,165
PS initiators, 38,099 AS initiators, 11,320 RS initiators, and 38,866 SS initiators.
Compared to other statin users, a higher percentage of PS initiatorswere aged75-85
(PS: 42.3%, SS: 41.0%, AS: 41.1%, RS: 38.0%, P0.01) andmore likely to be female (PS:
56.6%, SS: 51.3%, AS: 51.5%, RS: 55.7%, P0.01). PS initiatorsweremore likely to have
atrial fibrillation (PS: 10.0%, SS: 9.4%, AS: 9.6%, RS: 8.6%, P0.01) and take warfarin
(PS: 11.7%, SS: 9.8%, AS: 10.4%, RS: 9.9%, P0.01) and triazoles (PS: 3.1%, SS: 2.4%, AS:
2.6%, RS: 2.8%, P0.01) in the baseline period. A higher percentage of PS initiators
took more than 3 unique medications 90-day prior to the index date (PS: 85.4%, SS:
81.8%, AS: 83.0%, RS: 83.9%, P0.01). After controlling for demographic and clinical
characteristics, use ofwarfarinwas associatedwith initiating PS comparedwith SS,
AS, and RS. Other predictors of PS initiation included prior history of atrial fibrilla-
tion, HIV infection and use of calcium channel blockers, ezetimibe, and fenofi-
brates over the 1-year pre-index period compared with AS and SS. CONCLUSIONS:
Patient profiles were different among PS users compared to other statin users.
Selected comorbidities and prior use of certain medications were significant pre-
dictors of PS initiation among a cohort of Medicare patients.
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OBJECTIVES: In 2008, therewere currently 6 statins available in theU.S.market and
more than 193million statin prescriptionswerewritten.We sought to examine the
patterns of statin use among privately insured commercial and Medicare patients
in the U.S. METHODS: A retrospective analysis was performed using MarketScan
Commercial and Medicare data from Jan. 2008 to Dec. 2008. Two cohorts were
created: 1) the commercial cohort (CC) and 2) the Medicare cohort (MC). Statin
scripts of minimum 30 day supply were extracted from the pharmacy claims data
and individual demographic and clinical information were linked from their med-
ical and administrative records. Prescription patternswere examined and analyses
by age and genderwere performed.RESULTS:Therewere 18million and 9.8million
statin prescriptions filled by the CC and MC, respectively. In both cohorts, simva-
statin accounted for the largest share of statin prescriptions (MC: 44.1%; CC: 44.0%),
followed by atorvastatin (MC: 31.6%; CC: 31.1%), rosuvastatin (MC: 7.8%; CC: 11.2%),
pravastatin (MC: 8.1%; CC: 6.5%), lovastatin (MC: 7.4%; CC: 6.6%) and fluvastatin
(MC: 0.9%; CC: 0.6%). The majority of statin prescriptions were for generics (MC:
59.6%; CC: 57.1%).The average annual number of statin prescription per user was
9.3 for the MC and 7.6 for the CC. In the CC, 58.1% of prescriptions were filled by
male, while 50.4% of prescriptions were filled by male in the MC. Diabetic patients
accounted for 35.2% of prescriptions in the MC, and 26.8% in the CC. Milligram
dosing distributions (mean; median; mode) were for simvastatin (MC:32.1; 20;20
CC:32.9;20;40); atorvastatin (MC:24.3;20;10 CC:24.7;20;10); rosuvastatin (MC: 12.7;
10;10 CC:13.1;10;10); and pravastatin (MC:37.6;40;40 CC:38.2;40;40). CONCLUSIONS:
This analysis suggests different statin use patterns by age, gender, and insurance.
Most frequently dispensed doses were 20 mg for simvastatin, 10 mg for atorvasta-
tin and rosuvastatin, and 40 mg for pravastatin.
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OBJECTIVES: To compare dosing patterns among patients in whom atorvastatin
(AS), simvastatin (SS), rosuvastatin (RS), or pravastatin (PS) was newly prescribed.
METHODS: Using a large US managed care database, study patients aged18 who
were newly prescribed AS, SS, RS, or PS between 10/01/2006-09/30/2007 were iden-
tified with a minimum 12 months pre- and 24 months post-index health plan
eligibility. A 6-month washout period free of use of any statin was applied to iden-
tify patients in whom statin therapy was newly prescribed. The index date was
defined as the date of the first prescription fill for statins and 4 cohortswere created
based on index statins: AS, SS, RS, or PS. Patients were followed up to 24 months
after the index date, and the average daily dose for 12 prescriptions per person,
average/median daily dose in each of the first 12 prescriptions, and the average
daily statin costs were compared among 4 cohorts. RESULTS: A total of 142,692
patientswere identified, comprised of 47,972 AS patients, 21,475 RS patients, 62,954
SS patients, and 10,291 PS patients. The average daily doses of all prescriptions
were 21.3mg for AS patients, 10.2mg for RS patients, 29.2mg for SS patients, and
34.6mg for PS patients. The average/median daily dose for the 1st and 12th pre-
scriptions were 20.8mg/20mg and 21.2mg/20mg for AS patients, 10.0mg/10mg and
10.5mg/10mg for RS patients, 28.4mg/20mg and 28.7mg/20mg for SS patients, and
32.8mg/40mg and 35.9mg/40mg for PS patients. The average daily statin costs for
the 1st and 12th prescriptions were $2.9 and $3.2 for AS patients, $2.7 and $3.1 for
RS patients, $1.5 and $0.8 for SS patients, and $1.4 and $0.9 for PS patients.
CONCLUSIONS: Patients initiating AS, RS, SS, and PS experienced little escalation
of their statin daily dosing over the 24-month follow-up period.
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